At a glance
ClinicalIndex Comparison RecordN/ACompleted· 35 enrolled
Drug / intervention
Tedizolid Phosphate 200 MG [Sivextro]drug
Likely dose
Tedizolid Phosphate 200 MG [Sivextro]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Cohort Study on Patients With Tedizolid Prolonged Therapy for Orthopedic Device Infections
In Brief
A clinical study evaluating Tedizolid Phosphate 200 MG [Sivextro] for Prosthetic Joint Infection. Completed, enrolled 35 participants across 2 sites.
Detailed Summary
Pilot study the aim of which is to obtain reliable data on the tolerance, compliance and efficacy of Tedizolid used as prolonged (≥ 6 weeks) monotherapy or in combination therapy for the treatment of patients with orthopedic device infections due to Gram positive cocci.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProsthetic Joint Infection
CountriesFrance
CollaboratorsEric SENNEVILLE M.D. Ph.D.
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartAug 2018
Primary CompletionOct 2020
Study CompletionAug 2021
TodayJul 2026
First PostedDec 19, 2017
Enrollment StartAug 28, 2018
Primary CompletionOct 22, 2020
Study CompletionAug 22, 2021
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.5 years ago
Interventions
Tedizolid Phosphate 200 MG [Sivextro]drug
Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.